Articles tagged with Cancer Medication
A Canadian study estimates that over one-third of cancer cases in Canada can be prevented through a combination of policymaking and education. The ComPARe project analyzed the burden of cancer in Canada caused by modifiable lifestyle, environmental, and infectious agent risk factors.
Researchers at MD Anderson Cancer Center discovered a small molecule drug, IACS-10759, that targets metabolic reprogramming and inhibits OXPHOS, leading to marked growth inhibition in ibrutinib-resistant mantle cell lymphoma cells. The study provides hope for patients with this incurable B-cell lymphoma.
A study published in Developmental Cell suggests that pairing YAP/TAZ inhibitors with another drug, such as trametinib, may extend their benefit to patients. The researchers found that YAP/TAZ promotes growth by regulating glucose metabolism in cancer cells.
Research reveals men treated for benign prostatic hyperplasia (BPH) with 5-α-reductase inhibitors experienced a two-year delay in prostate cancer diagnosis and were twice as likely to have advanced disease. PSA suppression from these medications led to delays in diagnosis, potentially resulting in worsened clinical outcomes.
A recent clinical trial at the Stephenson Cancer Center found that patients with stage two, three, or four ovarian cancer can expect about 75 months of survival when their tumors are completely removed. The treatment regimen that caused fewer difficult side effects was just as effective as those with more severe side effects.
Researchers found that tumor mutation score is associated with responses to immunotherapy in metastatic colorectal cancer patients. Patients with high mutation scores are more likely to respond to immunotherapy, while those with low scores may benefit from chemotherapy.
A study at UT MD Anderson Cancer Center identified a new therapeutic target in cancer cells, caseinolytic protease P (ClpP), which breaks down proteins within mitochondria. New anti-cancer agents called imipridones activate ClpP and cause cancer cell death via mitochondrial proteolysis.
A new Australian study aims to develop a framework for effective care to reduce cardiovascular disease in breast cancer survivors. The two-year project will create an integrated model of care, embedding cardiovascular risk management into breast cancer treatment.
Researchers at Penn Medicine found that chronic circadian disruption triggers cell proliferation and shifts the cell-cycle balance, leading to tumor growth. The study also suggests that timing cancer treatment according to an individual's circadian rhythm can improve disease outcomes.
A new study reveals that disrupting normal circadian rhythms promotes tumor growth and suppresses the effects of a tumor-fighting drug. Circadian rhythm disruption increases cell proliferation by activating key proteins involved in cell cycle regulation.
The global HER2 testing survey reveals major access and affordability issues in low and middle income countries, with some upper middle income countries also affected. The study suggests that governments need better information to set planning priorities for investing in infrastructure, testing, and treatment.
A recent study published in JAMA Network Open shows that precision medicine can be a reality for pediatric tumours, identifying genomic anomalies to guide treatment and offer targeted therapies. The TRICEPS project has successfully enrolled 84 patients, leading to better patient management and more effective treatment options.
Researchers found that combining tumor-selective angiotensin blockers with immune checkpoint blockers significantly improves breast cancer treatment in mouse models. The combination treatment normalizes the tumor microenvironment, inducing changes in gene expression and activating immunosupportive pathways.
Researchers have discovered a protein, YTHDF2, that plays a key role in acute myeloid leukaemia (AML), but not in healthy blood cells. This discovery holds promise for novel treatments with fewer side effects than current chemotherapy.
The WINTHER trial successfully matched personalized therapy to 35% of patients with advanced cancer, showing improved overall survival for those with a high degree of matching. The trial's strategy employed RNA expression testing to tailor treatment based on gene expression differences between tumors and normal tissues.
A new zebrafish model has been developed to visualize drug responses at single-cell resolution in live animals, identifying a promising treatment for rhabdomyosarcoma. The model allows for the assessment of combination therapies and direct visualization of drug responses, reducing costs and time required for clinical trials.
A Phase II trial led by the University of Texas MD Anderson Cancer Center reports a 90% response rate for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp. The treatment was effective regardless of prior therapy, and survival rates were relatively high at 59% and 52% at 18 and 24 months, respe...
A clinical trial has shown that targeted therapy tagraxofusp is effective in treating blastic plasmacytoid dendritic-cell neoplasm (BPDCN), a rare and aggressive blood cancer. The therapy, which targets the CD123 protein, has been approved by the FDA for use in BPDCN patients.
Researchers have created a new nanomachine that can deliver specific drugs to parts of the body with tight access barriers, such as pancreatic cancer and brain tumors. The Y-shaped block catiomer is less than one-fifth the size of previous nanoparticles, allowing it to pass through smaller gaps.
Researchers found that over two-thirds of atheists shed their label after a transformative experience, and most attributed long-term positive changes in life satisfaction and purpose. The study also revealed vivid memories of the encounter, with many participants reporting communication with a conscious entity and decreased fear of death.
Researchers found that treating patients with personalized, combination therapies improved response rates and overall survival in patients with therapy-resistant cancers. Highly matched patients showed a 50% response rate compared to unmatched or less well-matched patients.
Researchers have identified three medicinal plants from Mauritius with effective inhibitors of esophageal cancer cells, stopping their growth and contributing to their death. The extracts contain natural chemical compounds that restrain the G2/M stages transition in malignant tumor cells by activating AMPK signaling pathway.
Researchers have developed a blood test that can identify genetic faults in cancer patients' blood, enabling clinicians to select targeted treatment options. The study showed that 11 out of 100 patients were successfully matched with molecularly matched clinical trials.
New research finds elevated levels of fatty acid transporter protein 2 (FATP2) in immune-suppressing cells, which can slow tumor growth and aid cancer treatments. The study also discovered an energy-granting lipid that FATP2 produces and traffics into cells, leading to its potential as a therapeutic target.
Research reveals that T-regulatory cells, which suppress the immune response, are driving tumor resistance to radiotherapy. Inhibiting EphB4-ephrinB2 interaction reduces T-reg cell activity, allowing immune cells to target cancer effectively.
A consortium of researchers identified a rare but important gene target, NRG1, responsible for development of various cancer types. The study suggests that targeting this gene fusion could effectively shut down cancers, offering a new therapy possibility.
Researchers combined CRISPR with drug discovery to understand how AML treatment works and which weaknesses can be exploited. The study revealed that LSD1-GFI1B relationship is critical for AML survival, enabling more targeted treatments.
Researchers have discovered that small molecule compounds can alter the spatial organization of the genome, potentially leading to new epigenetic cancer drugs. This breakthrough opens up a promising approach to treat cancer by changing the 3D genome structure.
Scientists successfully blocked cancer-fighting gene silencing protein UHRF1, restoring hundreds of protective genes in human colon cancer cells. The findings suggest a new strategy for fighting cancers by targeting this protein.
Researchers discovered that cancer cells can hide from immunotherapy by altering the levels of a key molecule on their surface. However, they identified an existing inhibitor of the WNT pathway that could potentially reverse this process and make cancer cells more visible to immune cells.
One-third of cancer patients use complementary and alternative medicines such as meditation, yoga, acupuncture, and herbal supplements. Many patients do not disclose their use to doctors due to lack of knowledge or perceived need for disclosure.
A nationwide survey found that 33.3% of cancer patients used complementary and alternative medicines, with herbal supplements being the most common. Many participants did not disclose their CAM use due to lack of physician inquiry or perceived unnecessary information.
Researchers at USC and UCLA have developed a new method to prevent damage to the jaw, a side effect of cancer treatment. The approach uses a different BP compound that can be used locally in the mouth to push the drug from the jawbone while leaving the useful drug undisturbed.
Researchers have identified chromogranin A as a key regulator of cardiotoxic and antitumor activities of Doxorubicin, a widely used cancer drug. Monitoring plasma levels of CgA before and after chemotherapy may provide prognostic information on drug-related cardiotoxicity.
Researchers used CRISPR technology to disrupt every gene in over 300 cancer models from 30 cancer types, discovering thousands of key genes essential for cancer's survival. The team developed a system to prioritize and rank 600 drug targets promising for development into targeted cancer treatments.
Cancer cells dependent on WRN enzyme to survive due to DNA repair system loss; MSI signature identified as effective biomarker for vulnerable tumors.
Researchers at UCSF have developed a new screening system to identify effective cancer-killers when combining drugs that are only partially effective as single-agent therapies. The study identified combinations of PI3K inhibitors and RNAi that eradicated a devastating blood cancer and certain solid tumor cells.
A comprehensive SWOG Cancer Research Network study has identified a host of targets for new or existing cancer drugs. The research, published in the Journal for ImmunoTherapy of Cancer, found higher counts of cancer-fighting TILs in pre-treatment tissue samples of breast cancer patients who achieved complete response to chemotherapy.
A recent study published in Nature Metabolism identified a novel pathway regulating drug tolerance in non-small-cell lung cancers with a specific mutation. MicroRNA miR-147b was found to mediate resistance to EGFR-based treatments, suggesting a potential new approach for treatment of lung cancer.
A USC study found that despite substantial media attention, most cancer drugs in shortage had little to no effect on chemotherapy treatment. Researchers analyzed over 2.4 million claims and found minimal change in treatment for the majority of oncology drugs during shortages.
A telerehabilitation program has been shown to improve the physical function, pain, and quality of life of patients with late-stage cancers. The study found that these patients who received remotely delivered rehabilitation services had fewer hospital and nursing home stays.
Researchers at Harvard Medical School and Dana-Farber Cancer Institute identify key molecules supporting lung cancer cell survival, demonstrating simultaneous inhibition of two signaling pathways. This approach could aid in designing drugs that selectively attack multiple proteins, beneficial for managing certain tumors.
A recent study in animal models of diffuse intrinsic pontine glioma (DIPG) has identified an experimental drug that effectively destroys DIPG cells by depleting cellular cholesterol. The researchers also found that the compound works by directly inhibiting lanosterol synthase, an enzyme involved in cholesterol production.
Researchers discovered that adiponectin, a hormone secreted by fat cells, protects female mice from liver cancer. In contrast, increased testosterone levels in male rodents reduce tumor growth and lower adiponectin levels.
Professor Jonas Bergh is recognized for his work on breast cancer biology, including tailored treatments and the impact of chemotherapy. He has made significant contributions to primary breast cancer treatment through his involvement in clinical trials and research collaborations.
Salk scientists discovered a new mechanism of action for the CDK12 protein, revealing its role in regulating gene expression and cell division. This finding suggests that targeting CDK12 could be an effective way to kill cancer cells and improve treatment outcomes.
Dr. Carl June receives the 2019 Harrington Prize for his contributions to CAR T therapy, a revolutionary cancer treatment. The prize honors his development of new strategies and culture systems that have enabled CAR T clinical trials.
A Phase II trial at MD Anderson Cancer Center showed umbralisib to be an effective treatment for patients with relapsed marginal zone lymphoma, achieving a 55% partial or complete response rate. The drug was well-tolerated, with a 71% progression-free survival after one year.
A new study by University of Pittsburgh researchers has identified a previously unknown mechanism used by tumors to suppress the immune system. The study found that tumors use two types of immune cells, regulatory T cells (Tregs), to release inhibitory cytokines, which activate a protein called BLIMP1 and disable killer T cells.
Early results from the UNITY-NHL phase II clinical trial show umbralisib to be highly active against relapsed/refractory marginal zone lymphoma, with a 55% partial or complete response rate and 71% progression-free survival at 12 months.
Researchers found that combining adavosertib with irinotecan, navitoclax or capecitabine increased its effectiveness against pancreatic cancer. The study aimed to identify new combinations of drugs to enhance adavosertib's effect.
Researchers found tarloxotinib effective against various cancer types, including ovarian and breast cancers with NRG1 gene fusions. The drug targets low-oxygen conditions, making it potentially more tolerable than existing therapies.
A University of Colorado Cancer Center study identifies a compound that inhibits the action of the SIX1/EYA transcriptional complex, which is involved in cancer metastasis. The compound dramatically suppresses breast cancer-associated metastasis in mouse models.
A combination of ipilimumab and nivolumab has been shown to shrink tumors in patients with high-grade neuroendocrine carcinoma by 42 percent, while all low-grade patients did not see a response.
Researchers found that the medicine DFMO not only blocks cell growth but also directly targets H. pylori to reduce its virulence. This could lead to a new strategy for preventing stomach cancer. The study supports further research into using DFMO to prevent stomach cancer.
Researchers have developed an experimental combined drug therapy that dramatically shrinks tumours and prevents metastasis in mice by targeting the DNA repair capability of cancer cells. The treatment has few side-effects compared to traditional chemotherapy and is being tested in clinical trials.
A national survey found that 81% of hospital pharmacy managers experienced medication hoarding due to drug shortages, with over two-thirds reporting more than 50 shortages. The survey highlights the need for more systematic approaches to address the issue and decrease rationing.
Researchers at Sanford Burnham Prebys have created a mouse model of choroid plexus carcinoma (CPC), a challenging type of brain cancer that affects young children. The study identified three promising drug compounds with biological activity, including dinaciclib and flavopiridol.
Researchers at Johns Hopkins Medicine have developed a new technique using PET scans to track the interaction between cancer drugs and tumor cells, providing valuable insights into how effective treatment is. This breakthrough could streamline cancer therapy by enabling doctors to tailor treatments, determine therapeutic doses, and avo...
Researchers will compare DNA from sepsis patients who died and survived to isolate signals and identify future drug targets. The study, funded by Sepsis Research, aims to better understand how genes govern sepsis recovery.